Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale

Leukemia

Volumn 30, Issue 9, 2016, Pages 1844-1852

  Cross, N C P ^a,b   White, H E ^a,b   Ernst, T ^c   Welden, L ^d   Dietz, C ^e   Saglio, G ^f   Mahon, F X ^g   Wong, C C ^h   Zheng, D ^h   Wong, S ^h   Wang, S S ^h   Akiki, S ⁱ   Albano, F ^j   Andrikovics, H ^k,l   Anwar, J ^m   Balatzenko, G ⁿ   Bendit, I ^o   Beveridge, J ^p   Boeckx, N ^q,r   Cerveira, N ^s   Cheng, S M ^t   Colomer, D ^u   Czurda, S ^v   Daraio, F ^f   Dulucq, S ^w   Eggen, L ^x   El Housni, H ^y   Gerrard, G ^z   Gniot, M ^aa   Izzo, B ^ab,ac   Jacquin, D ^ad   Janssen, J J W M ^ae   Jeromin, S ^af   Jurcek, T ^ag   Kim, D W ^ah   Machova Polakova, K ^ai   Martinez Lopez, J ^aj   McBean, M ^ak   Mesanovic, S ^al   Mitterbauer Hohendanner, G ^am   Mobtaker, H ^ad   Mozziconacci, M J ^an   Pajic T ^ao   Pallisgaard, N ^ap   Panagiotidis, P ^aq   Press, R D ^ar   Qin, Y Z ^as   Radich, J ^at   Sacha, T ^au   Touloumenidou, T ^av   Waits, P ^aw   Wilkinson, E ^ax   Zadro, R ^ay   Muller M C ^e   Hochhaus, A ^c   Branford, S ^d,az,ba   more..

^a SALISBURY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d University of Adelaide   (Australia)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY OF TURIN   (Italy)

^g UNIVERSITÉ DE BORDEAUX   (France)

^h NOVARTIS PHARMA K K   (Japan)

ⁱ West Midlands Regional Genetics Laboratory   (United Kingdom)

^j UNIVERSITY OF BARI   (Italy)

^k Hungarian National Blood Transfusion Service   (Hungary)

^l SEMMELWEIS UNIVERSITY   (Hungary)

^m KING S COLLEGE HOSPITAL   (United Kingdom)

ⁿ National Specialized Hospital for Active Treatment of Hematological Diseases   (Bulgaria)

^o UNIVERSITY OF SÃO PAULO   (Brazil)

^p FIONA STANLEY HOSPITAL   (Australia)

^q UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^r UNIVERSITY OF LEUVEN   (Belgium)

^s PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^t QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^u HOSPITAL CLÍNIC   (Spain)

^v CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^w BORDEAUX UNIVERSITY HOSPITAL   (France)

^x OSLO UNIVERSITY HOSPITAL   (Norway)

^y ERASME HOSPITAL   (Belgium)

^z HAMMERSMITH HOSPITAL   (United Kingdom)

^aa POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^ab UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^ac CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^ad Genoptix Inc   (United States)

^ae VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^af MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^ag UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^ah The Catholic University of Korea   (South Korea)

^ai INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^aj HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^ak PETER MACCALLUM CANCER CENTRE   (Australia)

^al UNIVERSITY CLINICAL CENTER TUZLA   (Bosnia and Herzegovina)

^am MEDICAL UNIVERSITY OF VIENNA   (Austria)

^an INSTITUT PAOLI CALMETTES   (France)

^ao UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^ap ZEALAND UNIVERSITY HOSPITAL   (Denmark)

^aq UNIVERSITY OF ATHENS   (Greece)

^ar OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^as PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^at Fred Hutchinson Cancer Research Center   (United States)

^au JAGIELLONIAN UNIVERSITY   (Poland)

^av G PAPANICOLAOU HOSPITAL   (Greece)

^aw Bristol Laboratory   (United Kingdom)

^ax LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^ay KBC Zagreb   (Croatia)

^az UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^ba UNIVERSITY OF ADELAIDE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BCR PROTEIN, HUMAN; BREAKPOINT CLUSTER REGION PROTEIN;

ABL1 GENE; ACCURACY; ARTICLE; BCR GENE; CONTROLLED STUDY; EVALUATION STUDY; GENE; GUSB GENE; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REFERENCE VALUE; REVERSE TRANSCRIPTION; SENSITIVITY ANALYSIS; CALIBRATION; GENETICS; ONCOGENE; STANDARD; STANDARDS; WORLD HEALTH ORGANIZATION;

CALIBRATION; FUSION PROTEINS, BCR-ABL; GENES, ABL; HUMANS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-BCR; REFERENCE STANDARDS; WORLD HEALTH ORGANIZATION;

EID: 84973097794     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.90     Document Type: Article

References (31)

1. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041-6051
2. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872-884
3. Hehlmann R, Muller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 2014; 32: 415-423
4. Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012; 30: 232-238
5. Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 2014; 123: 1353-1360
6. Branford S, Seymour JF, Grigg A, Arthur C, Rudzki Z, Lynch K et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 2007; 13: 7080-7085
7. O'Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E et al. Chronic myelogenous leukemia, version 1.2015. J Natl Compr Canc Netw 2014; 12: 1590-1610
8. Muller MC, Erben P, Saglio G, Gottardi E, Nyvold CG, Schenk T et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia 2008; 22: 96-102
9. Muller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009; 23: 1957-1963
10. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423-1432
11. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28-37
12. Branford S, Fletcher L, Cross NC, Muller MC, Hochhaus A, Kim DW et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008; 112: 3330-3338
13. Cross NC, Hochhaus A, Muller MC. Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization. Ann Hematol 2015; 94 (Suppl 2): S219-S225
14. White HE, Matejtschuk P, Rigsby P, Gabert J, Lin F, Lynn Wang Y et al. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood 2010; 116: e111-e117
15. Brown JT, Laosinchai-Wolf W, Hedges JB, Watt CD, Van Deerlin VM, Fletcher L et al. Establishment of a standardized multiplex assay with the analytical performance required for quantitative measurement of BCR-ABL1 on the international reporting scale. Blood Cancer J 2011; 1: e13
16. ELITechGroup. Philadelphia P210 RNA reference package insert, 2013
17. Yang R, Paparini A, Monis P, Ryan U. Comparison of next-generation droplet digital PCR (ddPCR) with quantitative PCR (qPCR) for enumeration of Cryptosporidium oocysts in faecal samples. Int J Parasitol 2014; 44: 1105-1113
18. Kim TG, Jeong SY, Cho KS. Comparison of droplet digital PCR and quantitative real-time PCR for examining population dynamics of bacteria in soil. Appl Microbiol Biotechnol 2014; 98: 6105-6113
19. Huggett JF, Foy CA, Benes V, Emslie K, Garson JA, Haynes R et al. The digital MIQE guidelines: minimum information for publication of quantitative digital PCR experiments. Clin Chem 2013; 59: 892-902
20. Clinical and Laboratory Standards Institute. Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline, 2nd edn. Clinical and Laboratory Standards Institute: Wayne, PA, 2012
21. Clinical and Laboratory Standards Institute. Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline, 2nd edn. Clinical and Laboratory Standards Institute: Wayne, PA, 2004
22. Clinical and Laboratory Standards Institute. Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline. Clinical and Laboratory Standards Institute: Wayne, PA, 2003
23. Thiers RE, Wu GT, Reed AH, Oliver LK. Sample stability: a suggested definition and method of determination. Clin Chem 1976; 22: 176-183
24. Rasmussen R. Quantification on the LightCycler. Rapid Cycle Real-Time PCR. Springer, 2001; pp 21-34
25. Raymaekers M, Smets R, Maes B, Cartuyvels R. Checklist for optimization and validation of real-time PCR assays. J Clin Lab Anal 2009; 23: 145-151
26. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-A Europe Against Cancer program. Leukemia 2003; 17: 2318-2357
27. Branford S, Hughes T. Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR. Methods Mol Med 2006; 125: 69-92
28. Jennings LJ, Smith FA, Halling KC, Persons DL, Kamel-Reid SMolecular Oncology Resource Committee of the College of American Pathologists. Design and analytic validation of BCR-ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease. Arch Pathol Lab Med 2012; 136: 33-40
29. Qiagen Inc. Summary of Safety and Effectiveness Data (SSED) of Artus CMV RGQ MDx Kit. U.S. Food and Drug Administration, 2014
30. Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia 2015; 29: 999-1003
31. Clark J, Jack A, Holden J, Barnett D, Reilly J. BCR-ABL1 Quantitation: To IS or not to IS, that is the question? Haematologica 2011; 96 (Suppl 2): S82